U.S. markets open in 1 hour 17 minutes
S&P Futures
4,159.50-5.25(-0.13%)Dow Futures
33,997.00-19.00(-0.06%)Nasdaq Futures
13,884.75-34.50(-0.25%)
Sierra Oncology, Inc. (SRRA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.70+0.31 (+1.78%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 17.39 |
| Open | 17.31 |
| Bid | 17.26 x 2900 |
| Ask | 19.47 x 800 |
| Day's Range | 17.30 - 17.76 |
| 52 Week Range | 10.02 - 20.43 |
| Volume | 7,288 |
| Avg. Volume | 34,385 |
| Market Cap | 205.824M |
| Beta (5Y Monthly) | 1.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.70 |
| Earnings Date | Mar 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 27.75 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- CNW Group
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
, March 23, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan.
- Simply Wall St.
Here's What Sierra Oncology, Inc.'s (NASDAQ:SRRA) Shareholder Ownership Structure Looks Like
A look at the shareholders of Sierra Oncology, Inc. ( NASDAQ:SRRA ) can tell us which group is most powerful. Insiders...
- PR Newswire
Sierra Oncology Reports 2020 Year End Results
Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operational results for the fourth quarter and fiscal year ended December 31, 2020.
© 2021 Verizon Media. All rights reserved.
